We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
An approval has been granted after the Valneva COVID-19 vaccine was found to meet the required safety, quality and effectiveness standards.
The COVID-19 vaccine developed by Valneva has today been given regulatory approval by the Medicines and Healthcare products Regulatory Agency (MHRA).
The UK’s independent medicines regulator is the first in the world to approve the Valneva vaccine which becomes the sixth COVID-19 vaccine to be granted an MHRA authorisation.
It is also the first, whole-virus inactivated COVID-19 vaccine to gain MHRA regulatory approval. With this type of vaccine, the virus is grown in a lab and then made completely inactive so that it cannot infect cells or replicate in the body but can still trigger an immune response to the COVID-19 virus. This process is widely used already in the production of flu and polio vaccines.
Our approval of the COVID-19 vaccine made by Valneva today follows a rigorous review of the safety, quality and effectiveness of this vaccine, and expert advice from the government’s independent scientific advisory body, the Commission on Human Medicines.
The independent Commission on Human Medicines and its COVID-19 Expert Working Group has carefully considered the available evidence are pleased to say that we have advised that the benefit risk balance is positive. The vaccine is approved for use in people aged 18 to 50 years, with the first and second doses to be taken at least 28 days apart.
Each type of vaccine has a different pattern of antibody response over time. For the Valneva vaccine, two doses are required before a robust antibody response is raised. This means that people will need to be made aware that protection will only start after two doses.
The storage temperature for the Valneva vaccine – of 2°C to 8°C – is similar to that of a domestic fridge, making it appropriate for use in countries where storage at very low temperatures is not possible.
If you are a member of the public or a healthcare professional, contact us on 020 3080 6000 (weekdays 9am to 5pm).
If you are a journalist, contact us on 020 3080 7651 (8.30am – 5pm) or 07770 446 189 (5pm– 830am and weekends):
News centre, MHRA, 10 South Colonnade, London, E14 4PU Email newscentre@mhra.gov.uk
For real-time updates including the latest press releases and news statements, see our Twitter channel at https://www.twitter.com/mhragovuk
Sharing will open the page in a new tab
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.
